meropenem trihydrate + vaborbactam: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
meropenem trihydrate + vaborbactam: clinical details
Prescribing considerations
- Confirm the likely pathogen, susceptibility and resistance mechanism; vaborbactam does not restore activity against NDM, VIM or OXA-48 carbapenemases.
- For aerobic Gram-negative infections with limited options, involve a clinician experienced in infectious diseases.
- Assess renal function, beta-lactam allergy history, seizure history, hepatic disease and sodium restriction before treatment.
- Consider additional or alternative cover if MRSA, MRSE or vancomycin-resistant enterococci are suspected.
Contraindications and cautions
- Hypersensitivity to meropenem, vaborbactam or an excipient
- Hypersensitivity to another carbapenem
- Previous severe hypersensitivity, including anaphylaxis or a severe skin reaction, to another beta-lactam antibacterial
Monitoring
- Renal function and clinically appropriate adjustment, including around haemodialysis
- Hepatic function and symptoms of drug-induced liver injury
- Neurological symptoms, particularly in patients with seizure disorders
- Diarrhoea suggestive of Clostridioides difficile infection and evidence of superinfection
- Relevant blood counts, electrolytes and interacting-medicine effects, including INR where applicable
Clinical pharmacology
Meropenem binds essential penicillin-binding proteins and inhibits bacterial cell-wall synthesis. Vaborbactam covalently inhibits class A and C serine beta-lactamases, including KPC. Both components are cleared mainly through the kidneys and are removed by haemodialysis.
Formulation and product differences
- The selected UK presentation is a powder for concentrate for intravenous infusion.
- It contains sodium carbonate and may be relevant to patients requiring sodium restriction.
- It requires reconstitution and further dilution in sodium chloride solution and is incompatible with glucose-containing solutions.
meropenem trihydrate + vaborbactam interactions
Give the clinical team a complete medicines list. Important interactions include:
Valproic acid, sodium valproate or valpromide
Carbapenems can sharply reduce valproate concentrations and cause loss of seizure control; concurrent use should generally be avoided or specialist anticonvulsant management arranged.
Probenecid
May reduce renal elimination and raise meropenem and vaborbactam concentrations; co-administration is not recommended.
Warfarin and other oral anticoagulants
Anticoagulant effect may change, so closer INR monitoring may be required during and shortly after treatment.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.